<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05111379</url>
  </required_header>
  <id_info>
    <org_study_id>350/T-2</org_study_id>
    <nct_id>NCT05111379</nct_id>
  </id_info>
  <brief_title>Acute Local Metabolomic Alterations in Blood and Muscle Tissue in Intermittent Claudication</brief_title>
  <official_title>Acute Local Metabolomic Alterations in Blood and Muscle Tissue in Intermittent Claudication</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Tartu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tartu University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Estonian Science Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Tartu</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The most common clinical presentation of lower extremity arterial disease is intermittent&#xD;
      claudication. Current understanding of the pathophysiology of intermittent claudication, as&#xD;
      well as its treatment options are limited. The progression of the disease may lead to lower&#xD;
      limb amputation, which is devastating for patients' quality of life and is a huge&#xD;
      socio-economic burden to society.&#xD;
&#xD;
      Current study allows to determine the acute local metabolomic alterations in the ischaemic&#xD;
      limb of the patient with intermittent claudication, and investigate the associations between&#xD;
      the metabolomic alterations and the patient's maximal walking distance. This provides&#xD;
      potentially valuable insight into the pathophysiology of this disease, and helps lay the&#xD;
      groundwork for identifying potential novel targets for instituting more effective therapies&#xD;
      for this high-risk population.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">August 2025</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in local metabolomic profile after treadmill exercise as reflected by arteriovenous gradients of low-molecular metabolites.</measure>
    <time_frame>Blood sampling at two points in time: Baseline (Day 1) &amp; 10-15 minutes after treadmill test (Day 2).</time_frame>
    <description>Measured using liquid chromatography combined with mass spectrometry (AbsoluteIDQ MxP Quant 500 Kit, BIOCRATES Life Sciences AG, Austria).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in local inflammatory profile after treadmill exercise as reflected by arteriovenous gradients of inflammatory mediators (IL-6, MPO, SOD, NOX isoform 1, NOX isoform 2, NOX isoform 5, nitrotyrosine, 8-iso-PGF2α).</measure>
    <time_frame>Blood sampling at two points in time: Baseline (Day 1) &amp; 10-15 minutes after treadmill test (Day 2).</time_frame>
    <description>Measured using enzyme linked immunosorbent assay. Measurement unit: ng/mL.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in local metabolomic profile after treadmill exercise as reflected by absolute concentrations of low-molecular metabolites in muscle biopsy.</measure>
    <time_frame>Biopsy at two points in time: Baseline (Day 1) &amp; 15-20 minutes after treadmill test (Day 2).</time_frame>
    <description>Measured using liquid chromatography combined with mass spectrometry (AbsoluteIDQ MxP Quant 500 Kit, BIOCRATES Life Sciences AG, Austria).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlations between maximal walking distance and exercise-induced changes in local metabolomic and inflammatory profiles.</measure>
    <time_frame>Data analysis after the enrollment period.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlations between baseline arterial functionality/hemodynamic parameters and exercise-induced changes in local metabolomic and inflammatory profiles.</measure>
    <time_frame>Data analysis after the enrollment period.</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Maximal walking distance on a treadmill (m).</measure>
    <time_frame>During treadmill test (Day 2).</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Ankle-brachial index (no units).</measure>
    <time_frame>Baseline (Day 1).</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Femoral artery intima-media thickness (mm).</measure>
    <time_frame>Baseline (Day 1).</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Peripheral blood pressure, central blood pressure (mmHg).</measure>
    <time_frame>Baseline (Day 1).</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Aortic pulse wave velocity (m/s).</measure>
    <time_frame>Baseline (Day 1).</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Aortic augmentation index (%).</measure>
    <time_frame>Baseline (Day 1).</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Identification of systemic metabolomic profile as reflected by absolute concentrations of low-molecular metabolites in peripheral blood sample.</measure>
    <time_frame>Blood sampling at one point in time: Baseline (Day 1)</time_frame>
    <description>Measured using liquid chromatography combined with mass spectrometry (AbsoluteIDQ MxP Quant 500 Kit, BIOCRATES Life Sciences AG, Austria).</description>
  </other_outcome>
  <other_outcome>
    <measure>Identification of systemic inflammatory profile as reflected by absolute concentrations of inflammatory mediators (IL-6, MPO, SOD, NOX isoform 1, NOX isoform 2, NOX isoform 5, nitrotyrosine, 8-iso-PGF2α) in peripheral blood sample.</measure>
    <time_frame>Blood sampling at one point in time: Baseline (Day 1)</time_frame>
    <description>Measured using enzyme linked immunosorbent assay. Measurement unit: ng/mL.</description>
  </other_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Peripheral Arterial Occlusive Disease Fontaine Stage IIa</condition>
  <arm_group>
    <arm_group_label>LEAD (Fontaine IIa)</arm_group_label>
    <description>Patients with mild intermittent claudication.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Healthy controls.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood, serum, plasma, frozen tissue.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with mild intermittent claudication (Fontaine IIa).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  LEAD group: Patients with diagnosis of lower extremity arterial disease (Fontaine&#xD;
             IIa).&#xD;
&#xD;
          -  Control group: Healthy volunteers with no leg symptoms and an ankle-brachial index&#xD;
             (ABI) of 1.0-1.4.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Fontaine stages I or IIb-IV&#xD;
&#xD;
          -  Exacerbation of limb ischaemia within the preceding 2 weeks;&#xD;
&#xD;
          -  strong rest pain of any cause;&#xD;
&#xD;
          -  age &lt;18 or &gt;80 years;&#xD;
&#xD;
          -  fasting &lt; 6 hours;&#xD;
&#xD;
          -  time since last use of tobacco products &lt; 6 hours;&#xD;
&#xD;
          -  body mass index ≥ 35 kg/m2&#xD;
&#xD;
          -  poor sonographic visibility of femoral artery;&#xD;
&#xD;
          -  angina;&#xD;
&#xD;
          -  cardiac arrhythmia at the time of presentation;&#xD;
&#xD;
          -  presence of cardiac pacemaker;&#xD;
&#xD;
          -  myocardial infarction within the preceding 3 months;&#xD;
&#xD;
          -  stroke within the preceding 6 months;&#xD;
&#xD;
          -  ongoing anticoagulant therapy;&#xD;
&#xD;
          -  ongoing dual antiplatelet therapy;&#xD;
&#xD;
          -  any revascularization within the preceding 3 month;&#xD;
&#xD;
          -  marked heart failure (NYHA III-IV);&#xD;
&#xD;
          -  blood pressure ≥ 180/110 mmHg;&#xD;
&#xD;
          -  blood pressure &lt;100/70 mmHg;&#xD;
&#xD;
          -  clinically significant heart valve disease;&#xD;
&#xD;
          -  acute infectious disease;&#xD;
&#xD;
          -  active malignancy or chemotherapy or disease-free &lt; 5 years;&#xD;
&#xD;
          -  type I diabetes or insulin therapy;&#xD;
&#xD;
          -  other clinically significant and untreated endocrine disorders;&#xD;
&#xD;
          -  moderate to severe bronchial asthma (GINA 2016);&#xD;
&#xD;
          -  severe chronic obstructive pulmonary disease (mMRC grade 3-4);&#xD;
&#xD;
          -  acute (KDIGO 2012) or chronic renal disease (eGFR-EPI &lt;30mL/min/1.73 m2);&#xD;
&#xD;
          -  acute or chronic liver disease;&#xD;
&#xD;
          -  anemia (&lt;110 g/L);&#xD;
&#xD;
          -  neuroinflammatory or neurodegenerative disease;&#xD;
&#xD;
          -  active rheumatism;&#xD;
&#xD;
          -  other diseases and factors that markedly hinder the subject's ability to walk during&#xD;
             the treadmill exercise.&#xD;
&#xD;
          -  For control group exclusively: history of lower extremity arterial disease / ABI &lt;1.0&#xD;
             or &gt;1.4.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jaak Kals, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Tartu</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kaido Paapstel, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Tartu</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kalle Kilk, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Tartu</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Holger Post, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Tartu</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jaak Kals, MD, PhD</last_name>
    <phone>+372 731 8292</phone>
    <email>jaak.kals@kliinikum.ee</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tartu University Hospital</name>
      <address>
        <city>Tartu</city>
        <state>Tartumaa</state>
        <zip>50406</zip>
        <country>Estonia</country>
      </address>
    </facility>
    <contact>
      <last_name>Jaak Kals, MD, PhD</last_name>
      <phone>+372 731 8292</phone>
      <email>jaak.kals@kliinikum.ee</email>
    </contact>
  </location>
  <location_countries>
    <country>Estonia</country>
  </location_countries>
  <link>
    <url>https://endothelialcentre.ut.ee/</url>
    <description>Endothelial Research Centre</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 28, 2021</study_first_submitted>
  <study_first_submitted_qc>November 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 8, 2021</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Tartu</investigator_affiliation>
    <investigator_full_name>Jaak Kals, MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>lower extremity arterial disease</keyword>
  <keyword>peripheral artery disease</keyword>
  <keyword>intermittent claudication</keyword>
  <keyword>local</keyword>
  <keyword>metabolism</keyword>
  <keyword>metabolomics</keyword>
  <keyword>arteriovenous gradients</keyword>
  <keyword>biomarkers</keyword>
  <keyword>inflammation</keyword>
  <keyword>ischemia-reperfusion injury</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intermittent Claudication</mesh_term>
    <mesh_term>Arterial Occlusive Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

